Haley Hedlin on Muck Rack

Haley Hedlin

Cambridge, Washington, D.C.
As seen in: Nature, Memory Studies, BMJ Open, MDPI, JAMA (The Journal of the American Medical Association), JAMA Internal Medicine Author Interviews, Medscape, Cell Press, The Lancet, medRxiv and
Public policy researcher, lawyer, and writer. Opinions are my own. MA Columbia & JD/MPP Harvard. simon.hedlin@post.harvard.edu
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Haley

Contact Haley, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil

|
By Fundação Oswaldo Cruz, Haley Hedlin, Amy Zhang, Curso de Enfermagem
| The Lancet Verified
Keywords COVID-19 vaccines Fractional doses Immunogenicity Non-inferiority study Evidence before this study We searched PubMed, Embase, and Cochrane Library, databases for studies published from December 1, 2019, to June 30, 2022, using the terms “COVID-19” or “SARS-CoV-2” and “vaccine” or “booster” or “fractional dose” or “dose sparing”.
Open in Who Shared Issue with article?

Errors in Figure 2

|
By Linda N Geng, Hector Bonilla, Haley Hedlin, Karen B. Jacobson
| JAMA Internal Medicine Author Interviews
Errors in Figure 2 Nirmatrelvir-Ritonavir and Symptoms of Postacute Sequelae of SARS-CoV-2 Infection Linda N. Geng, MD, PhD; Hector Bonilla, MD; Haley Hedlin, PhD; Karen B. Jacobson, MD; Lu Tian, DSc; Prasanna Jagannathan, MD; Phillip C. Yang, MD; Aruna K. Subramanian, MD; Jane W. Liang, PhD; Sa Shen, PhD; Yaowei Deng, MA; Blake J.
Open in Who Shared Issue with article?

Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial

|
By Linda N Geng, Hector Bonilla, Haley Hedlin, Karen B. Jacobson
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question What is the efficacy of 15 days of nirmatrelvir-ritonavir for improving select symptoms of postacute sequelae of SARS-CoV-2 infection (PASC)?
Open in Who Shared Issue with article?
See all 16 licensed articles (18 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified